Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Louis Bourgeois

Showing results (41-50 of 70) with videos related to

Pageof 7
Sort By:
NPJ Vaccines|February 1, 2025
Safety and immunogenicity in humans of enterotoxigenic Escherichia coli double mutant heat-labile toxin administered intradermallyMarcela F Pasetti, Patricia L Milletich, Jessica A White, et al.
Vaccine|December 20, 2018
A Phase 1 dose escalating study of double mutant heat-labile toxin LTR192G/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by sublingual or oral immunizationDavid I Bernstein, Marcela F Pasetti, Rebecca Brady, et al.
Plos One|March 29, 2018
Clinical endpoints in the controlled human challenge model for Shigella: A call for standardization and the development of a disease severity scoreChad K Porter, Amanda Lynen, Mark S Riddle, et al.
The Journal of Infectious Diseases|June 2, 2011
Volunteer challenge with enterotoxigenic Escherichia coli that express intestinal colonization factor fimbriae CS17 and CS19Robin McKenzie, Chad K Porter, Joyce A Cantrell, et al.
Plos Neglected Tropical Diseases|October 3, 2025
Intestinal inflammation induced by heat-labile toxin-producing enterotoxigenic E: Coli infection and impact on immune responses in an experimental human challenge modelXueyan Zhang, Jessica Brubaker, Kawsar R Talaat, et al.
Infection and Immunity|January 24, 2006
Comparative safety and immunogenicity of two attenuated enterotoxigenic Escherichia coli vaccine strains in healthy adultsRobin McKenzie, A Louis Bourgeois, Fayette Engstrom, et al.
Infection and Immunity|January 21, 2010
Assessment of the duration of protection in Campylobacter jejuni experimental infection in humansDavid R Tribble, Shahida Baqar, Daniel A Scott, et al.
Microorganisms|October 28, 2023
Efficacy of an Enterotoxigenic <i>Escherichia coli</i> (ETEC) Vaccine on the Incidence and Severity of Traveler's Diarrhea (TD): Evaluation of Alternative Endpoints and a TD Severity ScoreNicole Maier, Shannon L Grahek, Jane Halpern, et al.
Plos One|March 4, 2016
An Evidenced-Based Scale of Disease Severity following Human Challenge with Enteroxigenic Escherichia coliChad K Porter, Mark S Riddle, Ashley N Alcala, et al.
Journal of Clinical Microbiology|March 8, 2005
Prevalence of norovirus among visitors from the United States to Mexico and Guatemala who experience traveler's diarrheaAmy R Chapin, Colleen M Carpenter, William C Dudley, et al.
Pageof 7

Showing results (41-50 of 70) with videos related to

Sort By:
Pageof 7
NPJ Vaccines|February 1, 2025
Safety and immunogenicity in humans of enterotoxigenic Escherichia coli double mutant heat-labile toxin administered intradermallyMarcela F Pasetti, Patricia L Milletich, Jessica A White, et al.
Vaccine|December 20, 2018
A Phase 1 dose escalating study of double mutant heat-labile toxin LTR192G/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by sublingual or oral immunizationDavid I Bernstein, Marcela F Pasetti, Rebecca Brady, et al.
Plos One|March 29, 2018
Clinical endpoints in the controlled human challenge model for Shigella: A call for standardization and the development of a disease severity scoreChad K Porter, Amanda Lynen, Mark S Riddle, et al.
The Journal of Infectious Diseases|June 2, 2011
Volunteer challenge with enterotoxigenic Escherichia coli that express intestinal colonization factor fimbriae CS17 and CS19Robin McKenzie, Chad K Porter, Joyce A Cantrell, et al.
Plos Neglected Tropical Diseases|October 3, 2025
Intestinal inflammation induced by heat-labile toxin-producing enterotoxigenic E: Coli infection and impact on immune responses in an experimental human challenge modelXueyan Zhang, Jessica Brubaker, Kawsar R Talaat, et al.
Infection and Immunity|January 24, 2006
Comparative safety and immunogenicity of two attenuated enterotoxigenic Escherichia coli vaccine strains in healthy adultsRobin McKenzie, A Louis Bourgeois, Fayette Engstrom, et al.
Infection and Immunity|January 21, 2010
Assessment of the duration of protection in Campylobacter jejuni experimental infection in humansDavid R Tribble, Shahida Baqar, Daniel A Scott, et al.
Microorganisms|October 28, 2023
Efficacy of an Enterotoxigenic <i>Escherichia coli</i> (ETEC) Vaccine on the Incidence and Severity of Traveler's Diarrhea (TD): Evaluation of Alternative Endpoints and a TD Severity ScoreNicole Maier, Shannon L Grahek, Jane Halpern, et al.
Plos One|March 4, 2016
An Evidenced-Based Scale of Disease Severity following Human Challenge with Enteroxigenic Escherichia coliChad K Porter, Mark S Riddle, Ashley N Alcala, et al.
Journal of Clinical Microbiology|March 8, 2005
Prevalence of norovirus among visitors from the United States to Mexico and Guatemala who experience traveler's diarrheaAmy R Chapin, Colleen M Carpenter, William C Dudley, et al.
Pageof 7